Axsome Logo.png
Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant Depression
August 09, 2021 07:00 ET | Axsome Therapeutics, Inc.
AXS-05 significantly delayed the time to relapse of depression compared to placebo (p=0.002, primary endpoint) AXS-05 significantly prevented relapse of depression over at least 6 months compared to...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Positive Results from the COMET-TRD Trial of AXS-05 in Patients with Treatment Resistant Depression
December 02, 2020 06:00 ET | Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 44% of patients at 2 weeks, 67% at 6 weeks (MADRS response), and sustained with long-term treatment Rapid and substantial...
axsomelogo-468x57.jpg
Axsome Therapeutics Presents Data from GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder at the 2020 American Society for Clinical Psychopharmacology Annual Meeting
May 29, 2020 07:00 ET | Axsome Therapeutics, Inc.
NEW YORK, May 29, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS)...
axsomelogo-468x57.jpg
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 08, 2020 07:00 ET | Axsome Therapeutics, Inc.
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Topline Results of the STRIDE-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications
March 30, 2020 06:00 ET | Axsome Therapeutics, Inc.
Achieves key secondary endpoints demonstrating rapid and statistically significant improvements in depressive symptoms on MADRS versus active comparator at Weeks 1, 2, and overall (key secondary...
axsomelogo-468x57.jpg
Axsome Therapeutics Initiates GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder
June 24, 2019 07:00 ET | Axsome Therapeutics, Inc.
First patient enrolled in placebo-controlled GEMINI study Topline results anticipated in 2H 2019 NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...